Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote ...

Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial designed to prove that its experimental drug for Dravet syndrome, a severe form of epilepsy, can both reduce ...

Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

According to Stoke Therapeutics, over 90% of patients with Dravet syndrome suffer from at least one non ... the potential of zorevunersen as the first disease modifying medicine that addresses the ...

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in ...

Stoke Therapeutics , Inc. STOK reported ... in children and adolescents aged two to 18 years with Dravet syndrome. STK-001 is Stoke Therapeutics’ novel proprietary antisense oligonucleotide with ...

Stoke Therapeutics: The First Gene Silencing Therapy For Dravet Syndrome Sep. 07, 2024 4:03 AM ET Stoke Therapeutics, Inc. (STOK) Stock TAK , OVID , TKPHF , STOK 6 Comments 1 Like Avisol Capital ...

Stoke Therapeutics, Inc., ... today announced that five abstracts related to the Company’ s work in Dravet syndrome will be presented at the American Epilepsy Society 2021 Annual Meeting, ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote. ... About Dravet Syndrome.

Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.